PolarityTE — FY2020 Earnings Presentation
11 slides from PolarityTE's earnings presentation, Mar 30, 2021
Slide 1: Fiscal Year 2020 Financial Results
SkinTE Fiscal Year 2020 Financial Results March 30, 2021
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and projections. PolarityTE, Inc., (the "Company") makes no express or implied representation or warrant as to the completeness of this information or, in the case of projections, as to their attainability or the accura
Slide 3: Opening Remarks
SkinTE Opening Remarks David Seaburg, Chief Executive Officer
Slide 4: Progress Update
Progress Update * IND Progress * On track to submit IND in 2"¢ half of 2021 * Capital Preservation and Efficiency * 2020 cash burn 33% lower than 2019 * Q4:20 cash burn 70% lower than Q4:19 * 2020 total operation expenses 47% lower than 2019 * 2020 stock based comp 77% lower than 2019 > Continued fo
Slide 5: Progress Update
Progress Update * Recent Financings * Current cash on balance sheet, including recent funds raised in January 2021, expected to fund business activities into third quarter of 2022 * Diabetic Foot Ulcer Randomized Clinical Controlled Trial * Data expected via presentation and press release at SAWC Sp
Slide 6: Fourth Quarter and Full Year 2020 Revenue Metrics
Fourth Quarter and Full Year 2020 Revenue Metrics Q4:20 vs Q3:20 * Total Revenue: ~$3.59 million; up 8% QoQ * SkinTE Revenue: ~$1.20 million; up 4% QoQ * Contract Services Revenue: ~$2.39 million; up 9% QoQ + Includes ~$1.86 million from COVID-19 test processing FY:20 vs FY:19 * Total Revenue: ~$10.
Slide 7: Regulatory Update
SkinTE Regulatory Update Richard Hague, President & COO
Slide 8: Financials
SkinTE Financials Jake Patterson, Interim CFO 2021 PolarityTE, Inc. All Rights Reserved.
Slide 9: Financials
Financials In US$ ‘000 (except per share 4Q 2020 1Q 2020 Q. 2019 figures) Total Revenues 3,590 Products 1,202 Services 2,388 R&D (2,297) G&A (5,477) S&M (1,395) Cash flow used in Operations (5,584)* Cash Investment into PPE (114) Cash, Cash Equivalents and ST 25,522 Investments *includes $761k of of
Slide 10: Questions
SkinTE Questions David Seaburg, CEO Richard Hague, President & COO Jake Patterson, Interim CFO
Slide 11: About SkinTE
2021 Pola About SkinTE® SkinTE is a human cellular and tissue-based product derived from a patient's own skin (autologous) intended for the repair, reconstruction, replacement, or supplementation of skin tissue. Aseptic surgical procedures and handling during skin harvest, wound preparation, and Ski